![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Catco Reinsurance Opportunities Fund Limited | LSE:CAT | London | Ordinary Share | BMG1961Q3242 | ORD USD0.00013716 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 24.00 | 13.00 | 35.00 | 24.00 | 24.00 | 24.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Unit Inv Tr, Closed-end Mgmt | 6.33M | 5.44M | 3.6440 | 6.59 | 35.84M |
RNS No 3723v CAMBRIDGE ANTIBODY TECHNOLOGY GROUP 9th November 1998 IMPRESSIVE CLINICAL DATA WITH CAT/BASF HUMAN ANTIBODY IN RHEUMATOID ARTHRITIS Melbourn, UK. Significant new data from clinical trials with D2E7, a fully human monoclonal antibody which neutralises TNFalpha, developed by CAT in conjunction with BASF Pharma, are presented today at the American College of Rheumatology in San Diego, California. The key points from these trials which involved over 140 patients with rheumatoid arthritis are as follows: a) D2E7 was both safe and effective in reducing disease activity when administered either by the intravenous (iv) or self-injected subcutaneous route. Both routes of administration achieved comparable results b) up to 80 per cent of patients achieved a clinically significant response during chronic treatment of up to six months (intravenous) or three months (subcutaneous) c) clinical response was maintained during chronic administration d) chronic treatment was given weekly subcutaneously, and at two weekly intervals or longer (depending on the response) in the iv study e) a dose response for D2E7 was observed after intravenous dosing with 0.5 mg/kg being the minimum effective dose. Doses between 1 and 10 mg/kg given iv yielded similar results. David Glover, CAT's Medical Director, said: "This is a clear demonstration of a clinically significant benefit from the first of a new generation of fully human monoclonal antibodies to enter clinical trials. It is an important validation of CAT's ability to develop human antibody drugs." BASF Pharma/Knoll are currently running clinical phase I and II trials in the US and Europe. For further information contact: Cambridge Antibody Technology Tel: +44 (0) 1763 263233 David Chiswell, Chief Executive Officer John Aston, Finance Director Dr David Glover, Medical Director HCC.De Facto Tel: +44 (0) 171 496 3300 City/Financial, Nicola How Trade/Scientific, Nikul Odedra Notes TNFalpha TNFalpha is a pro-inflammatory cytokine found in the human body. It is believed to increase tissue damage in inflammatory diseases such as rheumatoid arthritis. D2E7 D2E7 is a fully human anti-TNFalpha neutralising monoclonal antibody developed by CAT in conjunction with BASF (Pharma). Results from three studies in patients with chronic rheumatoid arthritis are being presented at the ACR meeting: - a double-blind, placebo controlled, single dose intravenous (iv) study in 120 patients - a follow on open label chronic iv dosing study for up to 12 months in 120 patients - a double-blind, placebo controlled, weekly subcutaneous dosing study in 24 patients Three further presentations describe the creation of D2E7 using CAT's phage antibody technology, the results with D2E7 in a transgenic mouse model of polyarthritis and the effects of D2E7 upon oxidative burst in inflammatory white blood cells from patients with rheumatoid arthritis. DAS & ACR DAS (Disease Activity Score) and ACR20 (American College of Rheumatology preliminary definition of improvement) are each measures of disease activity for rheumatoid arthritis. Whilst the two are different they each take into account various measures of disease activity such as tender joint count, swollen joint count, assessment of pain, assessment of general health, assessment of disease activity and rate of settlement of red blood cells out of blood. CAT/BASF (Pharma) In collaboration with BASF Pharma, CAT isolated and optimised an antibody against TNFalpha. BASF Pharma are developing and commercialising the antibody and are responsible for clinical trials. CAT receives milestones and royalties from BASF. In addition, CAT has a collaborative deal with BASF Pharma/Genetics Institute to develop an anti-IL-12 (Interleukin 12) fully human monoclonal antibody for the treatment of inflammatory disorders; this antibody is currently in the pre-clinical phase. Anti-IL-12 antibodies could have application in a number of severe autoimmune and inflammatory diseases. CAT CAT is a UK biotechnology company using its proprietary technologies in fully human monoclonal antibodies for drug discovery and drug development. CAT is based in Melbourn, 10 miles south of Cambridge, England, and currently employs over 140 people. In March 1997, CAT completed its initial public offering and listing on the London Stock Exchange, raising approximately #41 million. CAT has a world-leading platform technology for rapidly isolating fully human monoclonal antibodies using phage display systems. CAT has an extensive phage display antibody library, currently incorporating around 100 billion distinct antibodies. This library forms the basis for the company's strategy to develop a portfolio of clinical development programmes and for discovering new drug leads using functional genomics. The first two antibody products developed by CAT started clinical trials in 1997, in inflammation and fibrosis. CAT has a number of license and collaborative agreements in place with pharmaceutical and biotechnology companies including: Eli Lilly, Pfizer, BASF Pharma, Genentech, ICOS Corporation, Genetics Institute/BASF Pharma, Mitsubishi Chemical, Progenitor and Obesys. END MSCUBGBUGBGRGBQ
1 Year Catco Reinsurance Opport... Chart |
1 Month Catco Reinsurance Opport... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions